Covid19 seq approches

Signal and Noise When I took the biostatistical course given by Dr. Thomas Love a few years ago, he recommended us reading a seemingly unrelavent stastical book “ The signal and the noise” by Nate Silver. The book is great and uncovers the promises and pitfalls of the big data analysis, one of the biggest pitfalls is that in most times what we...

Coming Therapies John Carroll at Endpoint recently selected 11 potential companies for near future “The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds”. Including Arrakis that I previously mentioned, Moderna’s potent rival BioNTech, see full list below. Arrakis Therapeutics Autolus BioNTech Cod...

Witness of a new era Moderna annouced their pre-clinical data entitled “Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia”. They showed positive results for methylmalonic acidemia/aciduria (MMA) murine models by treating with codon-optimized human methylmalonyl-CoA mutase (hMUT) mRNA. This, however is not even counted as ...

The next success in RNA-therapeutics? Yesterday, Arrakis Therapeutics announced exclusive license to RNA-targeted small molecule technology from the University of Pennsylvania. From The RNA Drug Hunter article, Arrakis had developed a compound that binds a three-way junction in an undisclosed RNA target. See David M. Chenoweth paper for more i...